ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.
- DOI
- 10.1016/j.jcf.2025.11.015
- Published
- 2026 Mar
- Container
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jcf.2025.11.015,
title = {ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.},
author = {Russell P and Woodward K and Morris D and Prasad N and White R and Wilkes D and Gosling M and Danahay H},
year = {2026},
journal = {Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society},
doi = {10.1016/j.jcf.2025.11.015},
url = {https://doi.org/10.1016/j.jcf.2025.11.015}
}RIS
TY - JOUR TI - ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial. AU - Russell P AU - Woodward K AU - Morris D AU - Prasad N AU - White R AU - Wilkes D AU - Gosling M AU - Danahay H PY - 2026 JO - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society DO - 10.1016/j.jcf.2025.11.015 UR - https://doi.org/10.1016/j.jcf.2025.11.015 ER -
APA
P, R., K, W., D, M., N, P., R, W., D, W., M, G., & H, D. (2026). ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. https://doi.org/10.1016/j.jcf.2025.11.015
Source records
- pubmed · retrieved 2026-09-26T13:28:48.974Z